Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ziv Haskal

Vascular & Interventional Radiology Charlottesville, VA Medical Doctor

NPI 1194760876 CMS profile 99365

Lee St Fl 1, Charlottesville, VA 22908

Open in the dashboard

General payments

$723,674

328 records reported · program years 2019–2025

Research payments

$450

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$538,024 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Ziv Haskal of Charlottesville, VA is reported in the CMS Open Payments database as having received $723,674 across 328 general payments and $450 in research payments paid to them. Separately, studies naming them as principal investigator received $538,024 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $208,943 143
2024 General $105,129 45
2023 General $71,194 32
2023 Research $450 1
2022 General $162,171 25
2021 General $58,983 29
2020 General $47,583 19
2019 General $69,671 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ziv Haskal
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Ziv Haskal were reported at $208,943. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Ziv Haskal Vascular & Interventional Radiology median Middle half National median
2019 $69,671 $422 $125–$1,555 $163
2020 $47,583 $200 $68–$652 $114
2021 $58,983 $280 $99–$866 $132
2022 $162,171 $433 $137–$1,497 $149
2023 $71,194 $506 $152–$2,019 $160
2024 $105,129 $556 $175–$1,930 $164
2025 $208,943 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bard Peripheral Vascular, Inc. $398,808 124 payments
  2. Boston Scientific Corporation $149,876 28 payments
  3. Sirtex Medical Inc $90,085 107 payments
  4. W. L. Gore & Associates, Inc. $47,501 40 payments
  5. Varian Medical Systems, Inc. $23,247 6 payments
  6. Cook Incorporated $4,830 2 payments
  7. Siemens Medical Solutions USA, Inc. $3,095 6 payments
  8. Genentech USA, Inc. $2,185 1 payment
  9. C. R. Bard, Inc. & Subsidiaries $1,425 2 payments
  10. Medtronic, Inc. $1,379 5 payments
  11. Other $1,244 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $334,004 115 payments
  2. Acquisitions $123,778 2 payments
  3. Royalty or License $123,045 4 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $70,230 19 payments
  5. Honoraria $39,306 5 payments
  6. Travel and Lodging $28,300 102 payments
  7. Food and Beverage $5,005 80 payments
  8. Gift $5 1 payment
Products named General payments · program years 2019–2025
  1. Liverty $123,045 4 payments
  2. General - Therapies $111,043 2 payments
  3. SIR-Spheres Microspheres $56,314 65 payments
  4. LAVA LES (Liquid Embolic System) $33,771 42 payments
  5. VIATORR TIPS Endoprosthesis $30,288 12 payments
  6. Product in Development $13,708 20 payments
  7. Radiation Oncology $11,880 1 payment
  8. OTHER $11,095 2 payments
  9. FLUENCY $10,913 3 payments
  10. General - Interventional Oncology $8,000 3 payments
  11. Other $26,821 51 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $450 1 payment

Billing to Medicare

Part B · data year 2024 · 131 billing codes

Paid by Medicare

$78,166

Of which drugs: $110

Medicare patients

326

Average age 72

Services billed

1,976

130 women, 196 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 44%
Arthritis 43%
Chronic kidney disease 41%
Diabetes 38%
Heart failure 38%
Atrial fibrillation 31%
Depression 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 11 1,085 $110

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

329 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record